# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

C. Measurand: Thyroid peroxidase autoantibodies (Anti-TPO), IgG

D. Type of Test: Quantitative Chemiluminescent Microparticle Immunoassay

E. Applicant: Fisher Diagnostics

F. Proprietary and Established Names: Architect® Anti-TPO Immunoassay Reagents Architect® Anti-TPO Calibrators and controls

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.5870, Thyroid Autoantibody Immunological Test System 21 CFR 862.1660, Quality Control Material (Assayed and Unassayed) 21 CFR 862.1150, Calibrator

2. Classification: Class II

3. Product code: JZO - Thyroid Antibody Test System JJX - Single (specified) Analyte Control (Assayed and Unassayed) JIT - Calibrator, Secondary

4. Panel: Immunology 82 Clinical chemistry 75

# H. Intended Use:

1. Intended use(s):

Architect® Anti-TPO is a chemiluminescent microparticle Immunoassay (CMIA) for the quantitative determination of the IgG class of thyroid peroxidase autoantibodies (antiTPO) in human serum and plasma (EDTA and Heparin) on the Architect® i System. The Architect® Anti-TPO assay is intended for use as an aid in the diagnosis of autoimmune thyroid disease.

The Architect®Anti-TPO Calibrators are for the calibration of the Architect® i System when used for the quantitative determination of IgG class of thyroid peroxidase autoantibodies (anti-TPO) in human serum and plasma. The Architect® Anti-TPO controls are for the estimation of test precision and the detection systematic analytical deviations of the Architect® $i$ System when used for the quantitative determination of IgG class of thyroid peroxidase autoantibodies (ant-TPO) in human serum and plasma.

2. Indication(s) for use:

Same as intended use.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: Architect i System (Architect® $i 2 0 0 0$ and Architect i 200SR).

# I. Device Description:

The device consists of (a) TPO coated paramagnetic particles, (b) sample diluent MES buffer with protein-goat, (c) Anti-human IgG (mouse monoclonal) acridinium labeled conjugate, (d) wash buffer, (e) Architect $i$ pre-trigger and trigger solutions,(f) calibrators, (g) controls and (h) a CD-ROM containing the assay files to be installed in the Architect $i$ System.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Abbott's AxSYM anti-Thyroid Microparticle Enzyme Immunoassay   
2. Predicate 510(k) number(s): k020348   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>aid in the diagnosis ofautoimmune thyroiddisease</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Number of Calibrators</td><td rowspan=1 colspan=1>6 levels (A-F)</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Calibrator Rangeconcentrations</td><td rowspan=1 colspan=1>0.0-1000 IU/mL</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Standardization material</td><td rowspan=1 colspan=1>NIBSC MRC 66/387Anti-Thyroid microsomeserum standard</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Control component</td><td rowspan=1 colspan=1>Human plasma</td><td rowspan=1 colspan=1>same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Thyroid peroxidase -microparticle coating</td><td rowspan=1 colspan=1>Recombinant</td><td rowspan=1 colspan=1>From human thyroidglands</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Mouse anti-human IgG(monoclonal) acridiniumlabeled in MES buffer</td><td rowspan=1 colspan=1>Goat anti-human IgGalkaline phosphate-inTRIS buffer</td></tr><tr><td rowspan=1 colspan=1>Control concentrationsand range</td><td rowspan=1 colspan=1>Negative 0.0IU/mLRange ≤ 2.15 IU/mLPositive 75 IU/mLRange 45-105 IU/mL</td><td rowspan=1 colspan=1>Negative 0.0 IU/mLRange ≤ 12.0 IU/mLPositive 75 IU/mLRange40-110 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Assay diluent</td><td rowspan=1 colspan=1>MES buffer</td><td rowspan=1 colspan=1>TRIS buffer</td></tr><tr><td rowspan=1 colspan=1>Assay method</td><td rowspan=1 colspan=1>Chemiluminescentmicroparticle (CMIA)</td><td rowspan=1 colspan=1>Microparticle enzyme(MEIA)</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>Architect i System</td><td rowspan=1 colspan=1>AxSYM System</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI (NCCLS) EP5-A, EP6-A, EP7-A, EP17-A.

# L. Test Principle:

Chemiluminescent microparticle immunoassay (CMIA) referred as Chemiflex. It is a two step assay. In the first step sample and assay diluent (MES buffer) and TPO coated paramagnetic particles are mixed and incubated. Anti-TPO in the sample binds to the microparticles. After a wash step anti-human acridinium labeled conjugate is added in the second step. Following an incubation and wash cycle pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units(RLU). A direct relationship exists between the amount of anti-TPO in the sample and the RLUs detected by the Architect $i$ system optics.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Precision studies were performed using Positive Control and 3 human panels (serum pools with low, medium and high concentrations), 3 lots of reagents in replicates of two at 2 separate times per day for 20 days on 3 instruments (according to CLSI EP5-A).

ARCHITECT Anti-TPO assay is designed to have an assay precision of $\leq 1 0 \%$ total CV for samples $\ge 5 . 6 1 ~ \mathrm { I U / m L }$ . Each reagent lot used a single calibration curve throughout the study. Data from this study are summarized in the following table.\*

<table><tr><td rowspan="2">Sample Instrument</td><td rowspan="2"></td><td rowspan="2">Reagent Lot</td><td rowspan="2">n</td><td rowspan="2">Mean Conc.</td><td colspan="2">Within Run</td><td colspan="2">Total</td></tr><tr><td>SD</td><td>% CV</td><td>SD</td><td>% CV</td></tr><tr><td rowspan="9">Positive Control</td><td rowspan="3">1</td><td>A</td><td>80</td><td>(IU/mL) 74.85</td><td>2.11</td><td>2.8</td><td>2.16</td><td>2.9</td></tr><tr><td>B</td><td>80</td><td>74.20</td><td>1.89</td><td>2.6</td><td>2.04</td><td>2.7</td></tr><tr><td>C</td><td>80</td><td>74.63</td><td>2.01</td><td>2.7</td><td>2.17</td><td>2.9</td></tr><tr><td rowspan="4">2</td><td>A</td><td>80</td><td>77.42</td><td>2.11</td><td>2.7</td><td>3.25</td><td>4.2</td></tr><tr><td>B</td><td>80</td><td>75.32</td><td>1.92</td><td>2.5</td><td>2.54</td><td>3.4</td></tr><tr><td>C</td><td>80</td><td>74.59</td><td>1.73</td><td>2.3</td><td>2.57</td><td>3.4</td></tr><tr><td>A</td><td>80</td><td>75.41</td><td>2.13</td><td>2.8</td><td>2.52</td><td>3.3</td></tr><tr><td rowspan="3">3</td><td>B</td><td>80</td><td>75.48</td><td>1.90</td><td>2.5</td><td>2.13</td><td>2.8</td></tr><tr><td>C</td><td>80</td><td>76.66</td><td>2.42</td><td>3.2</td><td>2.87</td><td>3.7</td></tr><tr><td rowspan="4">1</td><td>A</td><td>80 80</td><td>1.57 1.46</td><td>0.08</td><td>4.8</td><td>0.10</td><td>6.5</td></tr><tr><td>B</td><td>80</td><td>1.64</td><td>0.06 0.09</td><td>3.8</td><td>0.09</td><td>5.8</td></tr><tr><td>C A</td><td>80</td><td>1.60</td><td>0.09</td><td>5.6 5.3</td><td>0.10</td><td>6.1</td></tr><tr><td rowspan="3">2</td><td></td><td>80</td><td>1.53</td><td>0.06</td><td></td><td>0.12</td><td>7.6</td></tr><tr><td>B</td><td>80</td><td>1.52</td><td>0.10</td><td>3.9</td><td>0.11</td><td>7.2</td></tr><tr><td rowspan="2"></td><td>C</td><td></td><td></td><td></td><td>6.7</td><td>0.12</td><td>7.7</td></tr><tr><td rowspan="2"></td><td>A</td><td>80</td><td>1.47 1.47</td><td>0.08</td><td>5.3</td><td>0.11</td><td>7.8</td></tr><tr><td>3</td><td>B C</td><td>80 80</td><td>1.52</td><td>0.07 0.14</td><td>4.7 9.5</td><td>0.13 0.15</td><td>8.5 9.8</td></tr><tr><td rowspan="9">Panel 2</td><td rowspan="3">1</td><td>A</td><td>80</td><td>(IU/mL) 20.98</td><td>0.65</td><td>3.1</td><td>0.76</td><td>3.6</td></tr><tr><td>B</td><td>80</td><td>21.14</td><td>0.61</td><td>2.9</td><td>0.66</td><td>3.1</td></tr><tr><td>C</td><td>80</td><td>21.51</td><td>0.71</td><td>3.3</td><td>0.75</td><td>3.5</td></tr><tr><td rowspan="3">2</td><td>A</td><td>80</td><td>21.27</td><td>0.61</td><td>2.9</td><td>0.98</td><td>4.6</td></tr><tr><td>B</td><td>80</td><td>21.62</td><td>0.66</td><td>3.0</td><td>0.90</td><td>4.2</td></tr><tr><td>C</td><td>80</td><td>20.82</td><td>0.67</td><td>3.2</td><td>0.85</td><td>4.1</td></tr><tr><td rowspan="3">3</td><td>A</td><td>80</td><td>21.00</td><td>0.73</td><td>3.5</td><td>0.86</td><td>4.1</td></tr><tr><td>B</td><td>80</td><td>21.77</td><td>0.60</td><td>2.7</td><td>0.84</td><td>3.8</td></tr><tr><td>C</td><td>80</td><td>21.24</td><td>0.70</td><td>3.3</td><td>0.89</td><td>4.2</td></tr><tr><td rowspan="9">Panel 3</td><td rowspan="3">1</td><td>A</td><td>80</td><td>214.78</td><td>5.14</td><td>2.4</td><td>6.48</td><td>3.0</td></tr><tr><td>B</td><td>80</td><td>221.79</td><td>4.73</td><td>2.1</td><td>5.82</td><td>2.6</td></tr><tr><td>C</td><td>80</td><td>216.71</td><td>5.36</td><td>2.5</td><td>6.36</td><td>2.9</td></tr><tr><td rowspan="4">2</td><td>A</td><td>80</td><td>219.32</td><td>4.41</td><td>2.0</td><td>8.61</td><td>3.9</td></tr><tr><td>B</td><td>80</td><td>224.54</td><td>4.04</td><td>1.8</td><td>13.37</td><td>6.0</td></tr><tr><td>C</td><td>80</td><td>218.73</td><td>5.76</td><td>2.6</td><td>13.18</td><td>6.0</td></tr><tr><td>A</td><td>80</td><td>212.91</td><td>6.11</td><td>2.9</td><td>6.84</td><td>3.2</td></tr><tr><td rowspan="2">3</td><td>B</td><td>80</td><td>225.46</td><td>5.15</td><td>2.3</td><td>5.67</td><td>2.5</td></tr><tr><td>C</td><td>80</td><td>228.17</td><td>5.80</td><td>2.5</td><td>7.09</td><td>3.1</td></tr></table>

# $b$ . Linearity/assay reportable range:

The assay was shown to be linear from 3.0 to $1 0 0 0 . 0 \mathrm { I U / m L }$ by the following study: three high sample pools (1000, 300, and $3 0 \mathrm { I U / m L }$ ) were combined with a low pool calibrator A to provide 9 test points. All test points were analyzed in replicates of 5 using a single reagent lot. Automated dilution was compared to a manual 1:2 dilution using 9 human specimens with anti-TPO levels that were greater than calibrator E $\left( 2 5 0 \mathrm { I U / m L } \right)$ . The manual dilution was done with Anti-TPO calibrator A. Summary of results is shown in the following table.

<table><tr><td>Sample</td><td>Automated Dilution</td><td>Manual Dilution</td><td></td></tr><tr><td>ID 1</td><td>(IU/mL)</td><td>(IU/mL) 859.27</td><td>% Recovery 100.2</td></tr><tr><td>2</td><td>861.25 684.49</td><td>703.64</td><td>97.3</td></tr><tr><td>3</td><td>844.36</td><td>847.62</td><td>99.6</td></tr><tr><td>4</td><td>724.55</td><td>757.09</td><td>95.7</td></tr><tr><td>5</td><td>709.46</td><td>688.49</td><td>103.1</td></tr><tr><td>6</td><td>1105.65</td><td>1106.18</td><td>100.0</td></tr><tr><td>7</td><td>948.43</td><td>931.80</td><td>101.8</td></tr><tr><td>8</td><td>840.77</td><td>851.72</td><td>98.7</td></tr><tr><td>9</td><td>966.48</td><td>998.44</td><td>96.8</td></tr></table>

High dose hook – Ten samples with anti-TPO concentrations of $3 4 5 8 \mathrm { I U / m L }$ to 17815 IU/mL were analyzed and results were reported as ${ > } 1 0 0 0 \ \mathrm { I U / m L }$ . No high dose

hook effect was observed.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The anti-TPO reference calibrator is traceable to the NIBSC 66/387 reference preparation. The anti-TPO reference calibrators are produced from the NIBSC 66/387 reference preparation with individual levels at 30.0, 15.0, 5.0, 1.5, 0.75, and 0.0 $\mathrm { I U / m L }$ . The proper weight fractions of the stock concentrate and calibrator diluent were mixed to form the individual levels anti-TPO master calibrator at 0.00, 5.0, 20.0, 62.5, 250.0, and $1 0 0 0 . 0 \mathrm { I U / m L }$ . The calibrators and controls are manufactured from human anti-TPO positive plasma pools.

Stability – Stability was established based on accelerated and real time studies on three lots of Calibrators at various temperatures (5, 25, 30, 35, -20 and $- 5 0 ^ { \circ } \mathrm { C }$ ).

Stability test results and graphs are in the submission. The results indicate storage stability for 12 months when stored at ${ } _ { - 1 0 ^ { \circ } \mathrm { C } }$ . On-board stability is 30 days. Stability of reagents stored at $2 { - } 8 ^ { \circ }$ is shown as 9 months.

d. Limit of Blank:

Limit of Blank was tested using 10 replicates of calibrator A and 4 replicates of calibrator B per run. The acceptance criterion was $\leq 1 . 0 \ \mathrm { I U / m L }$ . 36 total runs were made across 3 instruments ( $i 2 0 0 0 )$ using 3 different reagent lots. The Limit of Blank was calculated as mean of all calculations plus 2 SDs for type 1 error of $2 . 5 \%$ . The Limit of Blank is $0 . 1 5 9 \mathrm { I U / m L }$ for all 3 lots.

e. Analytical specificity:

Interference from elevated levels of bilirubin $( 2 0 \mathrm { m g / d l } )$ , hemoglobin $\mathrm { 1 0 0 0 m g / d l ) }$ triglycerides $\mathrm { ( 1 0 0 0 m g / d l ) }$ and total protein $1 0 \mathrm { g / d l }$ ) were tested. A study was performed based on CLSI EP7-A. Specimens with anti-TPO levels between 45.07 and $3 6 1 . 6 4 \mathrm { I U / m L }$ were used. Specimens were spiked between 133.44 and 568.78 $\mathrm { I U / m L }$ . The average interference observed ranged from $- 3 . 6 \%$ to $+ 3 . 7 \%$ (within $\leq 1 5 \%$ acceptable range).

$f .$ Assay cut-off: Values greater than $5 . 6 ~ \mathrm { I U / m L }$ are considered positive.

2. Comparison studies:

a. Method comparison with predicate device: The performance of the Architect Anti-TPO was compared to AxSYM Anti-TPO assay. A total of 500 specimens (236 samples from healthy individuals and 264 samples from patients with autoimmune thyroid disease- 125 Graves’ disease and 139 Hashimoto’s Disease) were evaluated. Specimens were tested in replicates of one using the Architect Anti-TPO assay with three reagent lots. 446 samples were $< 1 0 0 0$ $\mathrm { I U / m L }$ . The remaining 54 samples were not included in the correlation since their anti-TPO concentrations were greater than the assay range $\mathrm { ( > 1 0 0 0 ~ I U / m L ) }$ ). Data from this study are summarized in the following table.

<table><tr><td rowspan=2 colspan=1>ARCHITECT Anti-TPO</td><td rowspan=1 colspan=3>AxSYM Anti-TPO</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>274</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>221</td><td rowspan=1 colspan=1>226</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1>500</td></tr></table>

Sample Range $( \mathrm { A R C H I T E C T } ) = 0 . 0$ to $2 7 4 3 0 . 8 \mathrm { I U / m L }$ Sample Range (AxSYM Anti-TPO) $= 1 . 5$ to $5 0 3 9 0 \mathrm { I U / m L }$   

<table><tr><td rowspan=1 colspan=5>Linear Regression Analysis</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>CorrelationCoefficient</td></tr><tr><td rowspan=1 colspan=1>AutoimmuneThyroid Disease</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>1.198(1.138 to1.259)</td><td rowspan=1 colspan=1>15.34(-3.25 to33.93)</td><td rowspan=1 colspan=1>0.937</td></tr><tr><td rowspan=1 colspan=1>ApparentlyHealthyIndividuals</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>0.924(0.909 to0.938)</td><td rowspan=1 colspan=1>-3.34(-4.35 to-2.34)</td><td rowspan=1 colspan=1>0.993</td></tr></table>

b. Matrix comparison:

Twenty donors were evaluated in each of the nine tubes – serum separator tube plus vs. serum, sodium heparin glass vs. serum, sodium heparin plastic vs. serum, lithium heparin glass vs. serum, lithium plastic vs. serum, plasma separator lithium heparin glass vs. serum, plasma separator lithium heparin plastic vs. serum, EDTA glass vs. serum and EDTA plastic vs. serum. For each donor, samples from each tube type were assayed in replicates of five. Samples from two donors with anti-TPO values greater than the assay range were excluded from the analysis. The mean percentage interference ranged from 1.16 to $1 . 8 \%$ . Linear regression analysis was also performed and results are summarized below.

Serum separator tube plus vs. serum, $\mathrm { y } = 1 . 0 1 7 8 \mathrm { x } - 2 . 7 9 3 9$ , $\mathrm { R } ^ { 2 } = 0 . 9 9 9 5$   
Sodium Heparin glass vs. serum, $\mathrm { y } = 1 . 0 0 3 6 \mathrm { x } + 1 . 1 4 4 8 ,$ $\operatorname { R } ^ { 2 } = 0 . 9 9 9 5$   
Sodium Heparin plastic vs. serum, $\mathrm { y } = 1 . 0 1 2 \mathrm { x } - 1 . 3 5 3 9 .$ , $\mathrm { R } ^ { 2 } = 0 . 9 9 9 5$   
Lithium Heparin glass vs. serum, $\begin{array} { r } { \mathrm { y } = 1 . 0 0 9 7 \mathrm { x } - 0 . 8 1 3 2 . } \end{array}$ , $\mathrm { R } ^ { 2 } = 0 . 9 9 9 6$   
Lithium Heparin plastic vs. serum, $\mathrm { y } = 1 . 0 1 6 3 \mathrm { x } - 2 . 0 5 6 5 ,$ $\operatorname { R } ^ { 2 } = 0 . 9 9 9 5$   
Plastic separator Lithium Heparin glass vs. serum, $\mathrm { y } = 1 . 0 0 7 \mathrm { x } - 0 . 9 6 4$ , $\mathrm { R } ^ { 2 } = 0 . 9 9 9 6$   
Plastic separator Lithium Heparin plastic vs. serum, $\mathrm { y } = 1 . 0 1 0 4 \mathrm { x } - 1 . 9 9 4$ , $\mathrm { R } ^ { 2 } = 0 . 9 9 9 6$   
EDTA glass vs. serum, $\mathrm { y } = 0 . 9 9 7 \mathrm { x } - 1 . 3 2 4 1$ , $\mathrm { R } ^ { 2 } = 0 . \dot { 9 9 9 8 }$   
EDTA plastic vs. serum, $\mathrm { y } = 1 . 0 0 8 8 \mathrm { x } - 1 . 2 8 2 6 , \mathrm { R }$ $\mathrm { R } ^ { 2 } = 0 . 9 9 9 3$

3. Clinical studies:

a. Clinical Sensitivity:

Clinical sensitivity was evaluated by testing 139 clinically defined Hashimoto’s Thyroiditis and 125 Grave’s Disease specimens. Anti-TPO levels $\ge 5 . 6 \mathrm { I U / m L }$ is considered positive for Architect assay and $\geq 1 2 \ \mathrm { I U / m L }$ for comparison assay.

The samples used in the method comparison study were from multiple collection sites and tested at the sponsor’s facility at two different timings noted as study 1 and study 2. The results are summarized below:

<table><tr><td rowspan=1 colspan=7>ARCHITECT Anti-TPO</td></tr><tr><td rowspan=1 colspan=4>Hashimoto&#x27;s Thyroiditis</td><td rowspan=1 colspan=3>Graves&#x27;Disease</td></tr><tr><td rowspan=1 colspan=1>Study#</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>% Positive(95% CI)</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>% Positive(95% CI)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>64.0(53.2 to 73.9)</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>92.0(83.4 to 97.0)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>74.0(59.7 to 85.4)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100.0(92.9 to 100.0)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>67.6(59.2 to 75.3)</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>95.2(89.8 to 98.2)</td></tr></table>

<table><tr><td rowspan=1 colspan=7>Comparison Assay-AxSYM Anti-TPO</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>85.4(76.3 to 92.0)</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>94.7(86.9 to 98.5)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>94.0(83.5 to 98.7)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100.0(92.9 to 100.0)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>88.5(82.0 to 93.3)</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>96.8(92.0 to 99.1)</td></tr></table>

There was a decrease in clinical sensitivity for Hashimoto’s Thyroiditis of $2 0 . 9 \%$ .

$b$ . Clinical specificity: Besides Grave’s and Hashimoto’s disease no other autoimmune diseases were tested.   
c. Other clinical supportive data (when a and b are not applicable): None

4. Clinical cut-off: 5.61 IU/mL

5. Expected values/Reference range:

Human serum specimens were collected from a population of 236 apparently healthy individuals. All specimens had TSH values within the normal reference range. Of this study population, 9 specimens delivered positive results on a commercially available antiTPO assay device and were excluded from further normal range analysis. The 97.5 percentile concentration of the remaining population was $5 . 6 1 ~ \mathrm { I U / m L }$ . In this study population, the normal range is $< 5 . 6 1 ~ \mathrm { I U / m L }$ . A total of $9 7 . 8 \%$ (222/227) of the population had values within this normal range.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.